Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants

被引：30

作者：

Baker, GB ^{[1
]}

Fang, J ^{[1
]}

Sinha, S ^{[1
]}

Coutts, RT ^{[1
]}

机构：

[1] Univ Alberta, Dept Psychiat, Neurochem Res Unit, Edmonton, AB T6G 2B7, Canada

来源：

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS | 1998年 / 22卷 / 02期

基金：

英国医学研究理事会;

关键词：

anticonvulsants; antidepressants; antipsychotics; anxiolytics; cytochrome P450; genetic polymorphism; isozymes; metabolism; selective serotonin reuptake inhibitors (SSRIs);

D O I：

10.1016/S0149-7634(97)00018-3

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

The Selective serotonin reuptake inhibitor (SSRI) antidepressants have become an important component of the therapeutic armamentarium in psychiatry and have attracted a great deal of public attention. Another interesting aspect of the SSRIs is their interaction with various isozymes of the cytochrome P450 (CYP) system which are responsible for metabolism of numerous drugs. This effect on the CYP isozymes has drawn attention to the importance of metabolic drug-drug interactions when dealing with drugs used to treat psychiatric disorders. Such interactions are of great relevance since psychiatry patients are frequently treated with multiple drugs and often these drugs undergo extensive biotransformation to metabolites which contribute to therapeutic and/or adverse effects. The present review deals with various aspects of metabolism mediated by CYP isozymes, particularly as they relate to pharmacokinetic interactions between the SSRIs and other drugs which are coadministered with them. (C) 1998 Elsevier Science Ltd. All rights reserved.

引用

页码：325 / 333

页数：9

共 155 条

[1] Paroxetine shifts imipramine metabolism [J].

Albers, LJ ;

Reist, C ;

Helmeste, D ;

Vu, R ;

Tang, SW .

PSYCHIATRY RESEARCH, 1996, 59 (03) :189-196

[2] CLINICAL PHARMACOKINETICS OF FLUOXETINE [J].

ALTAMURA, AC ;

MORO, AR ;

PERCUDANI, M .

CLINICAL PHARMACOKINETICS, 1994, 26 (03) :201-214

[3]

[Anonymous], TXB PSYCHOPHARMACOLO

[4]

ARANOW RB, 1989, AM J PSYCHIAT, V146, P911

[5] TRICYCLIC ANTIDEPRESSANT PLASMA-LEVELS AFTER AUGMENTATION WITH CITALOPRAM - A CASE-STUDY [J].

BAETTIG, D ;

BONDOLFI, G ;

MONTALDI, S ;

AMEY, M ;

BAUMANN, P .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (04) :403-405

[6] METABOLISM AND CHIRALITY IN PSYCHOPHARMACOLOGY - INTRODUCTION [J].

BAKER, GB ;

COUTTS, RT ;

HOLT, A .

BIOLOGICAL PSYCHIATRY, 1994, 36 (04) :211-213

[7] CLINICAL PHARMACOKINETICS OF CITALOPRAM AND OTHER SELECTIVE SEROTONERGIC REUPTAKE INHIBITORS (SSRI) [J].

BAUMANN, P .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 6 :13-20

[8] Pharmacology and pharmacokinetics of citalopram and other SSRIs [J].

Baumann, P .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 :5-11

[9] COMPARATIVE PHARMACOKINETICS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS - A LOOK BEHIND THE MIRROR [J].

BAUMANN, P ;

ROCHAT, B .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :15-21

[10]

Baumann P, 1995, REV CONTEMP PHARMACO, V6, P287

← 1 2 3 4 5 6 7 8 9 10 →